Assessment of the proarrhythmic risk associated with drugs that prolong the QT interval is difficult. We hypothesized that the proarrhythmic activities of drugs with very low to moderate risk of causing torsades de pointes would be well differentiated when the late sodium current (I NaL ) was greater than normal. The effects of selected QT-prolonging drugs on electrical activity of female rabbit isolated hearts were determined in the absence and presence of sea anemone toxin (ATX-II; an enhancer of I NaL ). I NaL recorded from ventricular myocytes isolated from female rabbit hearts was slightly increased by 1 and 3 nM ATX-II (n ϭ 13, P Ͻ 0.01). ATX-II (1 nM) prolonged the duration of the monophasic action potential (MAPD 90 ) of the isolated heart by 19 Ϯ 3% (P Ͻ 0.001, n ϭ 31) and shifted the concentration-response relationships for cisapride (1-30 nM), ziprasidone (0.01-3 M), quinidine (0.1-1 M), and moxifloxacin (0.01-1 M) to prolong MAPD 90 to the left by 2-to 12-fold. In contrast, the increases in MAPD 90 caused by 1 nM ATX-II and pentobarbital were only additive, and the increases in MAPD 90 caused by ATX-II and ranolazine [(Ϯ)-N-(2,6-dimethylphenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine] were less than additive. Episodes of arrhythmic activity were commonly observed, and beat-to-beat variability of action potential duration was increased, during exposure of hearts to cisapride, ziprasidone, quinidine, and moxifloxacin but not during exposure of hearts to ranolazine or pentobarbital, in the presence of ATX-II. Thus, in the female rabbit heart, ATX-II potentiated the effects of QT-prolonging drugs to increase MAPD 90 and unmasked the proarrhythmic activities of these drugs at clinically relevant drug concentrations.